{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:13:31Z","timestamp":1792293211188,"version":"4.4.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hodgkin lymphoma is a highly curable disease. Although most patients achieve complete response following frontline therapy, key unmet clinical needs remain including relapsed\/refractory disease, treatment-related morbidity, impaired quality of life and poor outcome in patients older than 60 years. The incorporation of novel therapies, including check point inhibitors and antibody\u2013drug conjugates, into the frontline setting, sequential approaches, and further individualized treatment intensity may address these needs. We summarize the current treatment options for patients with classical Hodgkin lymphoma from frontline therapy to allogeneic hematopoietic stem cell transplantation and describe novel trials in the field.<\/jats:p>","DOI":"10.1038\/s41408-021-00518-z","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T06:03:11Z","timestamp":1625810591000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0189-8233","authenticated-orcid":false,"given":"Razan","family":"Mohty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9my","family":"Dulery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0243-4040","authenticated-orcid":false,"given":"Abdul Hamid","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malvi","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama Al","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,9]]},"reference":[{"key":"518_CR1","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1200\/JCO.2003.07.001","volume":"21","author":"JM Connors","year":"2003","unstructured":"Connors JM. Hodgkin\u2019s lymphoma: the hazards of success. J Clin Oncol. 2003;21:3388\u201390.","journal-title":"J Clin Oncol."},{"key":"518_CR2","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1093\/annonc\/mdt413","volume":"24","author":"B Klimm","year":"2013","unstructured":"Klimm B, Goergen H, Fuchs M, von Tresckow B, B\u00f6ll B, Meissner J, et al. Impact of risk factors on outcomes in early-stage Hodgkin\u2019s lymphoma: an analysis of international staging definitions. Ann Oncol. 2013;24:3070\u20136.","journal-title":"Ann Oncol."},{"key":"518_CR3","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin\u2019s disease. International Prognostic Factors Project on Advanced Hodgkin\u2019s Disease. N Engl J Med. 1998;339:1506\u201314.","journal-title":"N Engl J Med."},{"key":"518_CR4","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMra1003733","volume":"363","author":"JO Armitage","year":"2010","unstructured":"Armitage JO. Early-stage Hodgkin\u2019s lymphoma. N Engl J Med. 2010;363:653\u201362.","journal-title":"N Engl J Med."},{"key":"518_CR5","first-page":"266","volume":"86","author":"G Jerusalem","year":"2001","unstructured":"Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin\u2019s disease. Haematologica. 2001;86:266\u201373.","journal-title":"Haematologica."},{"key":"518_CR6","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","volume":"25","author":"A Gallamini","year":"2007","unstructured":"Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin\u2019s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746\u201352.","journal-title":"J Clin Oncol."},{"key":"518_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","volume":"107","author":"M Hutchings","year":"2006","unstructured":"Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52\u20139.","journal-title":"Blood."},{"key":"518_CR8","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s00259-014-2783-x","volume":"41","author":"S Kanoun","year":"2014","unstructured":"Kanoun S, Rossi C, Berriolo-Riedinger A, Dygai-Cochet I, Cochet A, Humbert O, et al. Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1735\u201343.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"518_CR9","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1182\/blood-2017-07-795476","volume":"131","author":"AS Cottereau","year":"2018","unstructured":"Cottereau AS, Versari A, Loft A, Casasnovas O, Bellei M, Ricci R, et al. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood. 2018;131:1456\u201363.","journal-title":"Blood."},{"key":"518_CR10","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.2016.70.9410","volume":"35","author":"S Sasse","year":"2017","unstructured":"Sasse S, Br\u00f6ckelmann PJ, Goergen H, Pl\u00fctschow A, M\u00fcller H, Kreissl S, et al. Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. J Clin Oncol. 2017;35:1999\u20132007.","journal-title":"J Clin Oncol."},{"key":"518_CR11","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","volume":"372","author":"J Radford","year":"2015","unstructured":"Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372:1598\u2013607.","journal-title":"N Engl J Med."},{"key":"518_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1182\/blood-2019-125249","volume":"134","author":"S Gillessenillessen","year":"2019","unstructured":"Gillessenillessen S, Pl\u00fctschow A, Fuchs M, Markova J, Greil R, Topp MS, et al. Dose-intensification in early unfavorable Hodgkin lymphoma: long-term follow up of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2019;134:129\u2013129.","journal-title":"Blood."},{"key":"518_CR13","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","volume":"30","author":"B von Tresckow","year":"2012","unstructured":"von Tresckow B, Pl\u00fctschow A, Fuchs M, Klimm B, Markova J, Lohri A, et al. Dose-intensification in early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012;30:907\u201313.","journal-title":"J Clin Oncol."},{"key":"518_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","volume":"22","author":"P Borchmann","year":"2021","unstructured":"Borchmann P, Pl\u00fctschow A, Kobe C, Greil R, Meissner J, Topp MS, et al. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:223\u201334.","journal-title":"Lancet Oncol."},{"key":"518_CR15","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","volume":"390","author":"P Borchmann","year":"2017","unstructured":"Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, et al. PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2017;390:2790\u2013802.","journal-title":"Lancet."},{"key":"518_CR16","doi-asserted-by":"crossref","unstructured":"Casasnovas O, Brice P, Bouabdallah R, Salles G, Stamatoulas A, Dupuis J, et al., editors. Final analysis of the AHL2011 randomized phase III LYSA study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma. EHA; 2018 06\/15\/18. EHA Library: EHA Library [Abstract]; 2018.","DOI":"10.1200\/JCO.2018.36.15_suppl.7503"},{"key":"518_CR17","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1182\/blood.V126.23.577.577","volume":"126","author":"O Casasnovasasasnovas","year":"2015","unstructured":"Casasnovasasasnovas O, Brice P, Bouabdallah R, Salles GA, Stamatoullas A, Dupuis J, et al. Randomized phase III study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: Interim Analysis of the AHL2011 Lysa Study. Blood. 2015;126:577\u20137.","journal-title":"Blood."},{"key":"518_CR18","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"374","author":"P Johnson","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A, Foss\u00e5 A, Berkahn L, Carella A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N Engl J Med. 2016;374:2419\u201329.","journal-title":"N Engl J Med."},{"key":"518_CR19","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","volume":"14","author":"A Younes","year":"2013","unstructured":"Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14:1348\u201356.","journal-title":"Lancet Oncol."},{"key":"518_CR20","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood.2019003127","volume":"135","author":"DJ Straus","year":"2020","unstructured":"Straus DJ, D\u0142ugosz-Danecka M, Alekseev S, Ill\u00e9s \u00c1, Picardi M, Lech-Maranda E, et al. Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood. 2020;135:735\u201342.","journal-title":"Blood."},{"key":"518_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2020-137089","volume":"136","author":"DJ Straus","year":"2020","unstructured":"Straus DJ, Dlugosz-Danecka M, Connors JM, Ill\u00e9s \u00c1, Picardi M, Lech-Mara\u0144da E, et al. Brentuximab vedotin with chemotherapy for patients with previously untreated, stage III\/IV classical Hodgkin lymphoma: 5-year update of the ECHELON-1 study. Blood. 2020;136:26\u20138.","journal-title":"Blood."},{"key":"518_CR22","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1182\/blood.2020007400","volume":"137","author":"PB Allen","year":"2021","unstructured":"Allen PB, Savas H, Evens AM, Advani RH, Palmer B, Pro B, et al. Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. Blood. 2021;137:1318\u201326.","journal-title":"Blood."},{"key":"518_CR23","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","volume":"6","author":"PJ Br\u00f6ckelmann","year":"2020","unstructured":"Br\u00f6ckelmann PJ, Goergen H, Keller U, Meissner J, Ordemann R, Halbsguth TV, et al. Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial. JAMA Oncol. 2020;6:872\u201380.","journal-title":"JAMA Oncol."},{"key":"518_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2020-138413","volume":"136","author":"PJ Br\u00f6ckelmann","year":"2020","unstructured":"Br\u00f6ckelmann PJ, Goergen H, Keller U, Meissner J, Trautmann K, Halbsguth TV, et al. Efficacy and safety of nivolumab and AVD in early-stage unfavorable Hodgkin lymphoma: extended follow-up from the GHSG Phase II Nivahl Trial. Blood. 2020;136:6\u20137.","journal-title":"Blood."},{"key":"518_CR25","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","volume":"31","author":"AJ Moskowitz","year":"2013","unstructured":"Moskowitz AJ, Hamlin PA Jr, Perales MA, Gerecitano J, Horwitz SM, Matasar MJ, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013;31:456\u201360.","journal-title":"J Clin Oncol."},{"key":"518_CR26","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.3109\/10428194.2013.776165","volume":"54","author":"H Ghesqui\u00e8res","year":"2013","unstructured":"Ghesqui\u00e8res H, Stamatoullas A, Casasnovas O, Morschhauser F, Gyan E, Gabarre J, et al. Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients. Leuk Lymphoma. 2013;54:2399\u2013404.","journal-title":"Leuk Lymphoma."},{"key":"518_CR27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/bjh.12120","volume":"160","author":"G Corazzelli","year":"2013","unstructured":"Corazzelli G, Angrilli F, D'Arco A, Ferrara F, Musto P, Guarini A, et al. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. Br J Haematol. 2013;160:207\u201315.","journal-title":"Br J Haematol."},{"key":"518_CR28","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1182\/blood-2019-129016","volume":"134","author":"H Ghesquieres","year":"2019","unstructured":"Ghesquieres H, et al. Prednisone, vinblastine, doxorubicin and bendamustine (PVAB) regimen in first line therapy for older patients with advanced-stage classical Hodgkin lymphoma: Results of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA). Blood. 2019;134:2832.","journal-title":"Blood."},{"key":"518_CR29","doi-asserted-by":"publisher","first-page":"e808","DOI":"10.1016\/S2352-3026(20)30275-1","volume":"7","author":"BD Cheson","year":"2020","unstructured":"Cheson BD, Bartlett NL, LaPlant B, Lee HJ, Advani RJ, Christian B, et al. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2020;7:e808\u2013e15.","journal-title":"Lancet Haematol."},{"key":"518_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1182\/blood-2020-136583","volume":"136","author":"CA Yasenchak","year":"2020","unstructured":"Yasenchak CA, Bordoni R, Patel-Donnelly D, Larson T, Goldschmidt J, Boccia RV, et al. Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients. Blood. 2020;136:18\u20139.","journal-title":"Blood."},{"key":"518_CR31","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","volume":"130","author":"JW Friedberg","year":"2017","unstructured":"Friedberg JW, Forero-Torres A, Bordoni RE, Cline V, Patel Donnelly D, Flynn PJ, et al. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged >\/=60 years with HL. Blood. 2017;130:2829\u201337.","journal-title":"Blood."},{"key":"518_CR32","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","volume":"341","author":"DC Linch","year":"1993","unstructured":"Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial. Lancet. 1993;341:1051\u20134.","journal-title":"Lancet."},{"key":"518_CR33","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet. 2002;359:2065\u201371.","journal-title":"Lancet."},{"key":"518_CR34","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30:2183\u20139.","journal-title":"J Clin Oncol."},{"key":"518_CR35","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1182\/blood-2019-123925","volume":"134","author":"A Stamatoullastamatoullas","year":"2019","unstructured":"Stamatoullastamatoullas A, Ghesquieres H, Clement filliatre L, Quittet P, Morschhauser F, Ribrag V, et al. Brentuximab vedotin in first refractory\/relapsed classical Hodgkin lymphoma patients treated by chemotherapy (ice) before autologous transplantation. Final analysis of phase II study. Blood. 2019;134:132\u2013132.","journal-title":"Blood."},{"key":"518_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1182\/blood-2019-123162","volume":"134","author":"AF Herreraerrera","year":"2019","unstructured":"Herreraerrera AF, Chen RW, Palmer J, Tsai NC, Mei M, Popplewell LL, et al. PET-adapted nivolumab or nivolumab plus ICE as first salvage therapy in relapsed or refractory Hodgkin lymphoma. Blood. 2019;134:239\u2013239.","journal-title":"Blood."},{"key":"518_CR37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2020-138434","volume":"136","author":"AJ Moskowitz","year":"2020","unstructured":"Moskowitz AJ, Shah G, Sch\u00f6der H, Ganesan N, Hancock H, Davey T, et al. Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. Blood. 2020;136:17\u20138.","journal-title":"Blood."},{"key":"518_CR38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","volume":"132","author":"AS LaCasce","year":"2018","unstructured":"LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132:40\u20138.","journal-title":"Blood."},{"key":"518_CR39","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","volume":"131","author":"AF Herrera","year":"2018","unstructured":"Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131:1183\u201394.","journal-title":"Blood."},{"key":"518_CR40","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/blood-2019-122576","volume":"134","author":"R Chenoskowitz","year":"2019","unstructured":"Chenoskowitz R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, et al. Brentuximab vedotin and nivolumab for relapsed or refractory classic Hodgkin lymphoma: long-term follow-up results from the single-arm phase 1\/2 study. Blood. 2019;134:238\u2013238.","journal-title":"Blood."},{"key":"518_CR41","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1182\/blood-2019-124866","volume":"134","author":"CA Yasenchakasenchak","year":"2019","unstructured":"Yasenchakasenchak CA, Bordoni R, Yazbeck V, Patel-Donnelly D, Anderson T, Larson T, et al. Phase 2 study of frontline brentuximab vedotin plus nivolumab in patients with Hodgkin lymphoma aged \u226560 years. Blood. 2019;134:237\u2013237.","journal-title":"Blood."},{"key":"518_CR42","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","volume":"132","author":"CH Moskowitz","year":"2018","unstructured":"Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132:2639\u201342.","journal-title":"Blood."},{"key":"518_CR43","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1016\/j.bbmt.2018.05.026","volume":"24","author":"A Nademanee","year":"2018","unstructured":"Nademanee A, Sureda A, Stiff P, Holowiecki J, Abidi M, Hunder N, et al. Safety Analysis of Brentuximab vedotin from the phase III AETHERA trial in Hodgkin lymphoma in the post-transplant consolidation setting. Biol Blood Marrow Transplant. 2018;24:2354\u20139.","journal-title":"Biol Blood Marrow Transplant."},{"key":"518_CR44","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/bjh.14316","volume":"175","author":"SD Ramsey","year":"2016","unstructured":"Ramsey SD, Nademanee A, Masszi T, Holowiecki J, Abidi M, Chen A, et al. Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma. Br J Haematol. 2016;175:860\u20137.","journal-title":"Br J Haematol."},{"key":"518_CR45","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1080\/10428194.2020.1728755","volume":"61","author":"J Kort","year":"2020","unstructured":"Kort J, Chidiac A, El Sayed R, Massoud R, Nehme R, Bazarbachi A, et al. Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed\/refractory Hodgkin lymphoma. Leuk Lymphoma. 2020;61:1732\u20135.","journal-title":"Leuk Lymphoma"},{"key":"518_CR46","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood.2019000215","volume":"134","author":"P Armand","year":"2019","unstructured":"Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, et al. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019;134:22\u20139.","journal-title":"Blood."},{"key":"518_CR47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood-2020-136384","volume":"136","author":"AF Herrera","year":"2020","unstructured":"Herrera AF, Chen L, Nieto Y, Holmberg L, Johnston PB, Mei M, et al. Consolidation with nivolumab and brentuximab vedotin after autologous hematopoietic cell transplantation in patients with high-risk Hodgkin lymphoma. Blood. 2020;136:19\u201320.","journal-title":"Blood."},{"key":"518_CR48","doi-asserted-by":"publisher","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","volume":"7","author":"CS Diefenbach","year":"2020","unstructured":"Diefenbach CS, Hong F, Ambinder RF, Cohen JB, Robertson MJ, David KA, et al. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1\/2 trial. Lancet Haematol. 2020;7:e660\u2013e70.","journal-title":"Lancet Haematol."},{"key":"518_CR49","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/hon.61_2629","volume":"37","author":"G Collins","year":"2019","unstructured":"Collins G, Horwitz S, Hamadani M, Samaniego F, Spira A, Caimi P, et al. Analysis of clinical determinants driving safety and efficacy of camidanlumab tesirine (ADCT-301, CAMI) in relapsed\/refractory (R\/R) classical Hodgkin Lymphoma (cHL). Hematol Oncol. 2019;37:95\u20137.","journal-title":"Hematol Oncol."},{"key":"518_CR50","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/blood-2020-137451","volume":"136","author":"AF Herrera","year":"2020","unstructured":"Herrera AF, Carlo-Stella C, Collins GP, Maddocks KJ, Bartlett NL, Savage KJ, et al. Preliminary results of a phase 2 study of Camidanlumab Tesirine (Cami), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2020;136:21\u20133.","journal-title":"Blood."},{"key":"518_CR51","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood.2019004701","volume":"136","author":"NL Bartlett","year":"2020","unstructured":"Bartlett NL, Herrera AF, Domingo-Domenech E, Mehta A, Forero-Torres A, Garcia-Sanz R, et al. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2020;136:2401\u20139.","journal-title":"Blood."},{"key":"518_CR52","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1200\/JCO.20.01342","volume":"38","author":"CA Ramos","year":"2020","unstructured":"Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2020;38:3794\u2013804.","journal-title":"J Clin Oncol."},{"key":"518_CR53","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/bmt.2016.349","volume":"52","author":"J Gauthier","year":"2017","unstructured":"Gauthier J, Castagna L, Garnier F, Guillaume T, Soci\u00e9 G, Maury S, et al. Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplant. 2017;52:689\u201396.","journal-title":"Bone Marrow Transplant."},{"key":"518_CR54","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41409-017-0018-z","volume":"53","author":"J Gauthier","year":"2018","unstructured":"Gauthier J, Poir\u00e9 X, Gac AC, Leclerc M, Guillaume T, Chalandon Y, et al. Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin\u2019s lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplant. 2018;53:400\u20139.","journal-title":"Bone Marrow Transplant."},{"key":"518_CR55","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/bjh.16182","volume":"188","author":"A Bazarbachi","year":"2020","unstructured":"Bazarbachi A, Boumendil A, Finel H, Castagna L, Dominietto A, Blaise D, et al. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma\u2014a LWP-EBMT study. Br J Haematol. 2020;188:745\u201356.","journal-title":"Br J Haematol."},{"key":"518_CR56","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/bjh.15152","volume":"181","author":"A Bazarbachi","year":"2018","unstructured":"Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Peggs KS, et al. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. Br J Haematol. 2018;181:86\u201396.","journal-title":"Br J Haematol."},{"key":"518_CR57","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3324\/haematol.2015.134213","volume":"101","author":"A Perrot","year":"2016","unstructured":"Perrot A, Monjanel H, Bouabdallah R, Quittet P, Sarkozy C, Bernard M, et al. Impact of post-brentuximab vedotin consolidation on relapsed\/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program. Haematologica. 2016;101:466\u201373.","journal-title":"Haematologica."},{"key":"518_CR58","doi-asserted-by":"publisher","first-page":"8005","DOI":"10.1200\/JCO.2020.38.15_suppl.8005","volume":"38","author":"J Kuruvillauruvilla","year":"2020","unstructured":"Kuruvillauruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson N, et al. KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R\/R cHL). J Clin Oncol. 2020;38:8005\u20138005.","journal-title":"J Clin Oncol."},{"key":"518_CR59","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","volume":"129","author":"RW Merryman","year":"2017","unstructured":"Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Perales MA, et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma. Blood. 2017;129:1380\u20138.","journal-title":"Blood."},{"key":"518_CR60","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1634\/theoncologist.2017-0004","volume":"22","author":"YL Kasamon","year":"2017","unstructured":"Kasamon YL, de Claro RA, Wang Y, Shen YL, Farrell AT, Pazdur R. FDA approval summary: nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma. Oncologist. 2017;22:585\u201391.","journal-title":"Oncologist."},{"key":"518_CR61","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","volume":"25","author":"A Ijaz","year":"2019","unstructured":"Ijaz A, Khan AY, Malik SU, Faridi W, Fraz MA, Usman M, et al. Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant. 2019;25:94\u20139.","journal-title":"Biol Blood Marrow Transplant."},{"key":"518_CR62","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejca.2019.04.006","volume":"115","author":"G Manson","year":"2019","unstructured":"Manson G, Mear JB, Herbaux C, Schiano JM, Casasnovas O, Stamatoullas A, et al. Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation. Eur J Cancer. 2019;115:47\u201356.","journal-title":"Eur J Cancer."},{"key":"518_CR63","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1182\/bloodadvances.2019001336","volume":"4","author":"C De Philippis","year":"2020","unstructured":"De Philippis C, Legrand-Izadifar F, Bramanti S, Giordano L, Montes de Oca C, Dul\u00e9ry R, et al. Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. Blood Adv. 2020;4:1242\u20139.","journal-title":"Blood Adv"},{"key":"518_CR64","doi-asserted-by":"publisher","unstructured":"Merryman RW, Castagna L, Giordano L Ho VT, Corradini P, Guidetti A, et al. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021. https:\/\/doi.org\/10.1038\/s41375-021-01193-6.","DOI":"10.1038\/s41375-021-01193-6"},{"key":"518_CR65","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1038\/s41375-020-0851-8","volume":"34","author":"JC Nieto","year":"2020","unstructured":"Nieto JC, Rold\u00e1n E, Jim\u00e9nez I, Fox L, Carabia J, Ort\u00ed G, et al. Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy. Leukemia. 2020;34:3420\u20135.","journal-title":"Leukemia."},{"key":"518_CR66","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1365-2141.2007.06759.x","volume":"139","author":"KS Peggs","year":"2007","unstructured":"Peggs KS, Sureda A, Qian W, Caballero D, Hunter A, Urbano-Ispizua A, et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol. 2007;139:70\u201380.","journal-title":"Br J Haematol."},{"key":"518_CR67","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.bbmt.2014.05.024","volume":"20","author":"E Sala","year":"2014","unstructured":"Sala E, Crocchiolo R, Gandolfi S, Bruno-Ventre M, Bramanti S, Peccatori J, et al. Bendamustine combined with donor lymphocytes infusion in Hodgkin\u2019s lymphoma relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20:1444\u20137.","journal-title":"Biol Blood Marrow Transplant."},{"key":"518_CR68","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/cncr.31755","volume":"125","author":"A Bazarbachi","year":"2019","unstructured":"Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Blaise D, et al. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: a report from the EBMT Lymphoma Working Party. Cancer. 2019;125:90\u20138.","journal-title":"Cancer."},{"key":"518_CR69","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","volume":"129","author":"C Herbaux","year":"2017","unstructured":"Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. 2017;129:2471\u20138.","journal-title":"Blood."},{"key":"518_CR70","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","volume":"130","author":"BM Haverkos","year":"2017","unstructured":"Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017;130:221\u20138.","journal-title":"Blood."},{"key":"518_CR71","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1111\/bjh.16738","volume":"190","author":"T Badar","year":"2020","unstructured":"Badar T, Astle J, Kakar IK, Zellner K, Hari PN, Hamadani M. Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression. Br J Haematol. 2020;190:e98\u2013e101.","journal-title":"Br J Haematol."},{"key":"518_CR72","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1023\/A:1008315525997","volume":"10","author":"JH Loge","year":"1999","unstructured":"Loge JH, Abrahamsen AF, Ekeberg O, Kaasa S. Reduced health-related quality of life among Hodgkin\u2019s disease survivors: a comparative study with general population norms. Ann Oncol. 1999;10:71\u20137.","journal-title":"Ann Oncol."},{"key":"518_CR73","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/S1470-2045(09)70258-X","volume":"10","author":"N Heutte","year":"2009","unstructured":"Heutte N, Flechtner HH, Mounier N, Mellink WA, Meerwaldt JH, Eghbali H, et al. Quality of life after successful treatment of early-stage Hodgkin\u2019s lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. Lancet Oncol. 2009;10:1160\u201370.","journal-title":"Lancet Oncol."},{"key":"518_CR74","doi-asserted-by":"crossref","unstructured":"Allen PB, et al. Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma. Blood. 2020;137:1318\u201326.","DOI":"10.1182\/blood.2020007400"},{"key":"518_CR75","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial. J Clin Oncol. 2018;36:1428\u201339.","journal-title":"J Clin Oncol."},{"key":"518_CR76","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1182\/blood-2019-125039","volume":"134","author":"RW Merrymanerryman","year":"2019","unstructured":"Merrymanerryman RW, Castagna L, Corradini P, Ho VT, Bond DA, Jaglowski S, et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after programmed cell death 1 (PD-1)\/programmed cell death ligand 1 (PD-L1) blockade for classical Hodgkin lymphoma: analysis of a large international cohort. Blood. 2019;134:775\u2013775.","journal-title":"Blood."},{"key":"518_CR77","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/bmt.2017.69","volume":"52","author":"J El Cheikh","year":"2017","unstructured":"El Cheikh J, Massoud R, Abudalle I, Haffar B, Mahfouz R, Kharfan-Dabaja MA, et al. Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplant. 2017;52:1074\u20137.","journal-title":"Bone Marrow Transplant"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00518-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00518-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00518-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T10:46:42Z","timestamp":1669891602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00518-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,9]]},"references-count":77,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["518"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00518-z","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,9]]},"assertion":[{"value":"23 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}